`
`
`0001
`
`MYLAN - EXHIBIT 1051
`Mylan et al. v. AstraZeneca
`IPR2015-01340
`
`
`
`hijklmnnmho
`
`IJKLMNOONPQLNOLRPLSNOTPUVKLQVWLWXYOLRPLNMZKPUVL
`XQSLV[RVQSLZVPZ\V]OL\NUVO^L_VLJOVLOTNVQTV`aXOVSL
`NQQPUXRNPQLRPLXSSKVOOLOPMVLPbLOPTNVRY]OLMPORL
`TcX\\VQdNQdLcVX\RcTXKVLNOOJVO^L_VLSNOTPUVKLXQSL
`SVUV\PZLaKVXeRcKPJdcLRKVXRMVQROLXQSLfQSLQVWLL
`WXYOLRPLSV\NUVKLRcVMLRPLXOLMXQYLZVPZ\VLXOLZPOONa\V^L
`_VLX\OPLXNMLRPLZKPUNSVLXLOcXKVcP\SVKLKVRJKQLRcXRL
`KVWXKSOLRcPOVLWcPLNQUVORLRcVNKLMPQVYgLRNMVLXQSLL
`NSVXOLNQLPJKLTPMZXQY^
`
`1 //0/
`
`5/<
` 50 =>
`
`1 >0E/ F>5//
`/
`
`
`*9 () )
`'
`$ $,
`" ,
`? , "$) +) "
` (
` * )" "9
`$+
`, ( * -
`
` + $ $
`"& ,
`
`$ !"A%+ )
` 9 )
`+ "
` )+
`$ (+ +
`+
`-
`
`./ 0// 12@4
`
`./ 0// 12G4
`
`
`
` !
` "#$ %"& "
`' (
`) *) )+
`
`'
`$ $) ,+
` ) , , -
`
` .
`
`/ 0// 1234
`
` 56/
`/ /0
`
` 1 6//
`=6
`
` <6/ 1/
`
` //
`
` ,)
`"+
` ,
` *
`7 $ $) , +' ),
` ,
`
` 8* ( 8$ 9-
`
`A)
` $ (+)
` +" $ $
`B
`
`, ,*
`*" + $ *
`
` $$%"& "+
` $-
`
`H
`$
`, $
`8
` , ,
` ), ( ($ ,) $ * ( )
`"#$
`
`$ -
`
`./ 0// 12:;
`
`./ 0// 123CD
`
`./ 0// 1234D
`
`0002
`
`
`
`Novartis Annual Report 2015 | 1
`p &
` $
`
q3
`
`CONTENTS
`hoon
`
`02
`04
`C@
`06
`CG
`08
`Cs
`C
`
`14
`16
`3G
`18
`3s
`19
`3
`3D
`
`24
`34
`@G
`4G
`
`44
`52
`GG
`;@
`
`62
`62
`s@
`64
`s@
`67
`sG
`s:
`
`76
`78
`:s
`79
`:
`85
`:D
`97
`;
`D:
`
`110
`114
`33C
`120
`33G
`129
`3@C
`130
`3@D
`133
`34C
`344
`
`140
`172
`3GC
`245
`3:@
`@G;
`
`260
`@sC
`
`CHAIRMAN’S LETTER
`CHIEF EXECUTIVE OFFICER’S LETTER
` E/
`KEY PERFORMANCE INDICATORS - CONSOLIDATED HIGHLIGHTS
`5=6 55E/
`2015 AT A GLANCE
`<015 > / / >>/
`@C3;
`STRATEGIC OVERVIEW
`Our Environment
`/ 66F
`
` &
` *
`Our Strategy
`Our Culture and Values
`
`
` ,9
`Our Portfolio
`
`~
` "H $
`
`
` (
`PERFORMANCE
`15
`Performance Summary
`Division Performance
`
`(
`* + **
`9
`} & $
`(
`* +
`INNOVATION
`Innovation Overview
` 6
` & &
`&
`Pipeline
`
`CORPORATE RESPONSIBILITY
` 1 /1 /0
`Managing Corporate Responsibility
`Innovation in Access
` , ,~
`
` $ $ 8 9
` & ++$$
`Expanding Access to Medicines
` " , ++$$ " + $
`Doing Business Responsibly
`} ,?$ $$$ $ 89
`CORPORATE GOVERNANCE REPORT
`Letter from the Chairman
` 1 61
`
`(
` * )~)
`*
`Summary of Our Corporate Governance Approach
`Our Shares and Our Shareholders
` **
`9 (
`~
`
` &
` +
` +)
`Our Board of Directors
`
` )
`$ "
` )
`) "
`$
`
`?
`" (}
`+
`$
`Our Management
`
` ,*
`COMPENSATION REPORT
` 1/ 1
`Compensation Committee Chairman's Introduction
`~ * $ ~ ** ~)
`* #$
` "+
`2015 Executive Committee Compensation System
`
`
`CONTENTS
`hoon
`
`02
`04
`C@
`06
`CG
`08
`Cs
`C
`
`14
`16
`3G
`18
`3s
`19
`3
`3D
`
`24
`34
`@G
`4G
`
`44
`52
`GG
`;@
`
`62
`62
`s@
`64
`s@
`67
`sG
`s:
`
`76
`78
`:s
`79
`:
`85
`:D
`97
`;
`D:
`
`110
`114
`33C
`120
`33G
`129
`3@C
`130
`3@D
`133
`34C
`344
`
`140
`172
`3GC
`245
`3:@
`@G;
`
`260
`@sC
`
`CHAIRMAN’S LETTER
`CHIEF EXECUTIVE OFFICER’S LETTER
` E/
`KEY PERFORMANCE INDICATORS - CONSOLIDATED HIGHLIGHTS
`5=6 55E/
`2015 AT A GLANCE
`<015 > / / >>/
`@C3;
`STRATEGIC OVERVIEW
`Our Environment
`/ 66F
`
` &
` *
`Our Strategy
`Our Culture and Values
`
`
` ,9
`Our Portfolio
`
`~
` "H $
`
`
` (
`PERFORMANCE
`15
`Performance Summary
`Division Performance
`
`(
`* + **
`9
`} & $
`(
`* +
`INNOVATION
`Innovation Overview
` 6
` & &
`&
`Pipeline
`
`CORPORATE RESPONSIBILITY
` 1 /1 /0
`Managing Corporate Responsibility
`Innovation in Access
` , ,~
`
` $ $ 8 9
` & ++$$
`Expanding Access to Medicines
` " , ++$$ " + $
`Doing Business Responsibly
`} ,?$ $$$ $ 89
`CORPORATE GOVERNANCE REPORT
`Letter from the Chairman
` 1 61
`
`(
` * )~)
`*
`Summary of Our Corporate Governance Approach
`Our Shares and Our Shareholders
` **
`9 (
`~
`
` &
` +
` +)
`Our Board of Directors
`
` )
`$ "
` )
`) "
`$
`
`?
`" (}
`+
`$
`Our Management
`
` ,*
`COMPENSATION REPORT
` 1/ 1
`Compensation Committee Chairman's Introduction
`~ * $ ~ ** ~)
`* #$
` "+
`2015 Executive Committee Compensation System
`
+ &~ ** ~ * $ 9$ *
`2015 Executive Committee Compensation
`
`2015 Executive Committee Compensation
`
+ &~ ** ~ * $
`2015 Board Compensation System
`
`2015 Board Compensation System
`
?
`"~ * $ 9$ *
`2015 Board Compensation
`
`"~ * $ 9$ *
`2015 Board Compensation
`
?
`"~ * $
`Compensation Governance
`~ * $ &
` +
`FINANCIAL REPORT
`51
`2015 Operating and Financial Review
`
`"~ * $
`Compensation Governance
`~ * $ &
` +
`FINANCIAL REPORT
`51
`2015 Operating and Financial Review
`
` , " + &
`Novartis Group Consolidated Financial Statements
`Financial Statements of Novartis AG
`p &
` $
` ~ $ " " + * $
` + * $ (p &
` $
`OTHER INFORMATION
` 5
`Key Dates 2016, Contact Information and Forward-Looking Statements
`r9} $
` , " + &
`Novartis Group Consolidated Financial Statements
`Financial Statements of Novartis AG
`p &
` $
` ~ $ " " + * $
` + * $ (p &
` $
`OTHER INFORMATION
` 5
`Key Dates 2016, Contact Information and Forward-Looking Statements
`r9} $
~ + (
`* "
`
`"% ' , * $
`
`0003
`
`5>>> 5
`
`
`p
`$ , $ ' )) $$ )
`
`"+ "$ )(
` , $
` ) $" "9" $ $ r 9 -
`
`
`
`./ 0// 12s3
`
`tuvwxyz{v|}
`-~) , $ )" $
`
`+
`"$ ) $ + + ** 9) $
`
` ) $ H *-}
`- ) $ ($
`" +
`$ ) " &
`*" + +
` *
` )
` * $ 9 ) +#* , )
`-
`
`0003
`
`
`* "
`
`"% ' , * $
`
`0003
`
`5>>> 5
`
`
`p
`$ , $ ' )) $$ )
`
`"+ "$ )(
` , $
` ) $" "9" $ $ r 9 -
`
`
`
`./ 0// 12s3
`
`tuvwxyz{v|}
`-~) , $ )" $
`
`+
`"$ ) $ + + ** 9) $
`
` ) $ H *-}
`- ) $ ($
`" +
`$ ) " &
`*" + +
` *
` )
` * $ 9 ) +#* , )
`-
`
`0003
`
`
`
`@qp &
` $
`
`
`¶·mjl·o¸nkk
`¹j
`
`IJKLORKXRVdNTLbPTJOL
`PQLOTNVQTV`aXOVSL
`NQQPUXRNPQLTPQRNQJVOL
`RPLdVQVKXRVLORKPQdL
`KVOJ\RO
`
`ºtvw{vx»¼zw½¾
`
`k k
`
`¡QL¢£¤¥gL¦PUXKRNOLTPMZ\VRVSLXLZPKRbP\NPLRKXQObPKMXRNPQLRPLbPTJOLPQLRcKVVL
`\VXSNQdLSNUNONPQOgLORKVQdRcVQLPJKLZcXKMXTVJRNTX\OLPZVKXRNPQgLXQSL\VUVKXdVLPJKL
`QVWLOVKUNTVOLPKdXQN§XRNPQLRPLNMZKPUVLZKPSJTRNUNRYLXQSLZKPfRXaN\NRY^L_VLX\OPL
`XTcNVUVSLNMZPKRXQRLMN\VORPQVOLNQLSVUV\PZNQdLPJKLZNZV\NQVLXQSLVQcXQTNQdLXTTVOOL
`RPLcVX\RcTXKV^L_VLaV\NVUVLRcVOVLORVZOLZPONRNPQLJOLWV\\LRPLQXUNdXRVLRcVLTcX\\VQdNQdL
`cVX\RcTXKVLVQUNKPQLMVQRLXQSLOJORXNQXa\YLdKPWLOX\VOgLZKPfROLXQSLSNUNSVQSO^
`
`
`$
` , +( +$ $+ +%8 $" & + $ ,
` $
` ,
`$ $-¨
`
` +)" $
` $ (
` "+ $ +" ,8
` ' )
` ,) )
` $$+) $)
` (
`*"%
`
` + ©ª«¬®«¯° "$
` $ $
` * ±¯®ª«²³-A)´+ & $$ (
`
` "+ $, &$$ )
`
`+ µ" +
` 9%(
`%
`(
`* +
` + ,* "$ ) +)+ ´
`+ * +8 µ $
`
`
`
` ) )+
`$9$ *$ "8 "
`$ )
`+$ *
`$-
`
` )$ * * 8
` " "
`
`$
`+) ""& *
` +
`9 )
`
`
` $ ( ** % + ,9 "
` $+ +-
` * + * "$ 8 )
` $) & )
`
` +) , )
` + + (*" + "
`$
` & , 8 * , ) "
`$ )
`
`µ"$ ( + ,9 "
` ,9-¨ "
`$ " ( )p &
` $ $ $(
`
`
`? " + $
`+) ) $
`
`9
" +
` + " ,$+ $ $-
`
`A) $
` (
`+
`
`$
`+)´
` $ $ $
`+ 8
` $ ) )
`
`$
`+)
`
` $ $-
`
` $ )) )+
` "$+ & &$ +
`' ) +) ,9 "
`$-
` *%
`
` ) &
`"
`
`$) $ &$ ,
` $ )
` * (,
`
`" , " )
`$+ ( (
`* +) ,9 ") )+
`-A)$
`$
`+)
` $
`
`* 9
` $(
`* $+ $ () )+
` "" $
` + & 8$ $$* "$-¨
`
`%
`
`
`" *8
` + "8 µ (
` * )$+) ,$-
`
` $ ) )+
` "
` $ ) &
`$ $ 8 9 ) *
` & ++$$ *" + $ "
`
`) )+
`(
` $
` " )
`"- $
` (
` ,%$ " ,+
`
`
`$ $ 8 9
`
` + & $ $ 9
` +)" )p &
` $ ++$$
` ( - $"$ , "
` & " ´
`" 8
`
`0004
`
`
` + " ,$+ $ $-
`
`A) $
` (
`+
`
`$
`+)´
` $ $ $
`+ 8
` $ ) )
`
`$
`+)
`
` $ $-
`
` $ )) )+
` "$+ & &$ +
`' ) +) ,9 "
`$-
` *%
`
` ) &
`"
`
`$) $ &$ ,
` $ )
` * (,
`
`" , " )
`$+ ( (
`* +) ,9 ") )+
`-A)$
`$
`+)
` $
`
`* 9
` $(
`* $+ $ () )+
` "" $
` + & 8$ $$* "$-¨
`
`%
`
`
`" *8
` + "8 µ (
` * )$+) ,$-
`
` $ ) )+
` "
` $ ) &
`$ $ 8 9 ) *
` & ++$$ *" + $ "
`
`) )+
`(
` $
` " )
`"- $
` (
` ,%$ " ,+
`
`
`$ $ 8 9
`
` + & $ $ 9
` +)" )p &
` $ ++$$
` ( - $"$ , "
` & " ´
`" 8
`
`0004
`
`
`
` E/
`
`p &
` $
`
q4
`
`hijknj·Ämk·ÅÅjh·¶
`
` ÆwyxÇÇxt»xǾt½xÇÈtuvw»vÉ
`
`tÆw{tz;tÍvz½x»{wtÉx»{
`
`FvzwvÈtyyx¾¾v½¾tËz¾xv»¾ÇÒ
`
`ÉzÊǾtxyËwtuvz»½v̾v»½
`
`zwvzÇtϼvz;¼ÈzwvÒÏtÈÆÇx»{
`
`zÇÇtÈxz¾vÇÒ¼vz;¼ÈzwvËzw¾»vwÇ
`
`ËvtËÍvEÇÍxuvÇÎ
`
`t»Ë¼zwyzÈvƾxÈzÍÇÒvÊvÈzwv
`
`z»½ÇtÈxv¾Êz¾Ízw{v¾txyËwtuv
`
`ÊÏtÈÆÇx»{t»ÇÈxv»ÈvÐÑzÇv½
`
`z»½{v»vwxÈÇÎ
`
`zÈÈvÇǾt¼vz;¼Èzwvz»½vÇÇv»¾xzÍ
`
`yv½xÈx»vÇzÇÉvzÇËxwv¾tÑvÈtyv
`
`x»»tuz¾xt»¾t½vÍxuvwÑv¾¾vw
`
`tÇÆËËtw¾¾¼vËÆwÇÆx¾tÏtÆw
`
`z¾wÆǾv½Ívz½vwx»È¼z»{x»{¾¼v
`
`tƾÈtyvÇÏtwËz¾xv»¾ÇzwtÆ»½¾¼v
`
`Ǿwz¾v{ÊÒÉvÏtǾvwzÈtwËtwz¾v
`
`ËwzȾxÈvtÏyv½xÈx»vÎ
`
`ÉtwͽÒÉv¼zuvvǾzÑÍxǼv½z
`
`ÈÆ;Æwvtϼx{¼v¾¼xÈzÍǾz»½zw½Ç
`
`Ǿwt»{ÈtyËv¾x¾xuvËtÇx¾xt»Î Æw
`
`z»½Ëwtyt¾vx»»tuz¾xt»ÒÓÆzÍx¾ÊÒ
`
`5twytwv½v¾zxÍt»tÆwǾwz¾v{ÊÒ
`
`zËËwtzȼÇvwuvǾ¼vx»¾vwvǾÇtÏ
`
`ÈtÍÍzÑtwz¾xt»ÒËvwÏtwyz»ÈvÒ
`
`ÇvvËz{v3sÎ
`
`tÆwǼzwv¼tͽvwÇz»½wvx»ÏtwÈvÇ
`
`ÈtÆwz{vz»½x»¾v{wx¾ÊÎ
`
`¿ À
` $"" & " "
`
` +
` $
`$)
`
`Á~Â
`
`
`hijknj·Ämk·ÅÅjh·¶
`
` ÆwyxÇÇxt»xǾt½xÇÈtuvw»vÉ
`
`tÆw{tz;tÍvz½x»{wtÉx»{
`
`FvzwvÈtyyx¾¾v½¾tËz¾xv»¾ÇÒ
`
`ÉzÊǾtxyËwtuvz»½v̾v»½
`
`zwvzÇtϼvz;¼ÈzwvÒÏtÈÆÇx»{
`
`zÇÇtÈxz¾vÇÒ¼vz;¼ÈzwvËzw¾»vwÇ
`
`ËvtËÍvEÇÍxuvÇÎ
`
`t»Ë¼zwyzÈvƾxÈzÍÇÒvÊvÈzwv
`
`z»½ÇtÈxv¾Êz¾Ízw{v¾txyËwtuv
`
`ÊÏtÈÆÇx»{t»ÇÈxv»ÈvÐÑzÇv½
`
`z»½{v»vwxÈÇÎ
`
`zÈÈvÇǾt¼vz;¼Èzwvz»½vÇÇv»¾xzÍ
`
`yv½xÈx»vÇzÇÉvzÇËxwv¾tÑvÈtyv
`
`x»»tuz¾xt»¾t½vÍxuvwÑv¾¾vw
`
`tÇÆËËtw¾¾¼vËÆwÇÆx¾tÏtÆw
`
`z¾wÆǾv½Ívz½vwx»È¼z»{x»{¾¼v
`
`tƾÈtyvÇÏtwËz¾xv»¾ÇzwtÆ»½¾¼v
`
`Ǿwz¾v{ÊÒÉvÏtǾvwzÈtwËtwz¾v
`
`ËwzȾxÈvtÏyv½xÈx»vÎ
`
`ÉtwͽÒÉv¼zuvvǾzÑÍxǼv½z
`
`ÈÆ;Æwvtϼx{¼v¾¼xÈzÍǾz»½zw½Ç
`
`Ǿwt»{ÈtyËv¾x¾xuvËtÇx¾xt»Î Æw
`
`z»½Ëwtyt¾vx»»tuz¾xt»ÒÓÆzÍx¾ÊÒ
`
`5twytwv½v¾zxÍt»tÆwǾwz¾v{ÊÒ
`
`zËËwtzȼÇvwuvǾ¼vx»¾vwvǾÇtÏ
`
`ÈtÍÍzÑtwz¾xt»ÒËvwÏtwyz»ÈvÒ
`
`ÇvvËz{v3sÎ
`
`tÆwǼzwv¼tͽvwÇz»½wvx»ÏtwÈvÇ
`
`ÈtÆwz{vz»½x»¾v{wx¾ÊÎ
`
`¿ À
` $"" & " "
`
` +
` $
`$)
`
`Á~Â
`
Ã
-
`
`
Ã
-
`
`) ,)%B 9*" + $ ""
`$$ )
` $ ,8
`" ( + ** + 8" $ $$$+) $
`
`" 8 $ "8
` $ + +
` "& ,+
` $-?$ "$" &
` , ""*" + $ ) $
`
`$ + 8$ $$* " *$ $
` ) )+
`$9$ *$ ")* , )
` $ ,+ $ (
`
`+
` " $+ * ++ $B +$-
`
` "" 9 + & &
`+
`
` , &
` + "
`"" + " ) + ,
`
`
` + $ )
`$ ') "
`$-A)?
`" (}
`+
`$ $(9+ ** " ) $ $'-¨
`
` *
` (
`+
`" &
`$ 9 "$ (,
`"
` " " + )
`$ (p &
` $ "
`
`
`$)
`) "
`$-A) $ )$8
`$ ") )+
`
`
`, ""89 ,
` 9 "
`
`
`
` " , "+ 8
` -
`
` ( )$´
` $* '$+ µ" ) + + $
` , )
`*
`' $
`
`
`
`) ,)%B 9*" + $ ""
`$$ )
` $ ,8
`" ( + ** + 8" $ $$$+) $
`
`" 8 $ "8
` $ + +
` "& ,+
` $-?$ "$" &
` , ""*" + $ ) $
`
`$ + 8$ $$* " *$ $
` ) )+
`$9$ *$ ")* , )
` $ ,+ $ (
`
`+
` " $+ * ++ $B +$-
`
` "" 9 + & &
`+
`
` , &
` + "
`"" + " ) + ,
`
`
` + $ )
`$ ') "
`$-A)?
`" (}
`+
`$ $(9+ ** " ) $ $'-¨
`
` *
` (
`+
`" &
`$ 9 "$ (,
`"
` " " + )
`$ (p &
` $ "
`
`
`$)
`) "
`$-A) $ )$8
`$ ") )+
`
`
`, ""89 ,
` 9 "
`
`
`
` " , "+ 8
` -
`
` ( )$´
` $* '$+ µ" ) + + $
` , )
`*
`' $
`
`
-
`
` ) '9 (
` )+ µ" +9 ) & +"
`+ * 9 " * $" 8 8
`
`
` $ " & " " +
` $ ( À ~
`
` ) '9 (
` )+ µ" +9 ) & +"
`+ * 9 " * $" 8 8
`
`
` $ " & " " +
` $ ( À ~
-
)
` ,-
`
`
`
` +
`9
`
`ºtvw{vx»¼zw½¾
`
`~)
`* ( )?
`" (}
`+
`$
`
`0005
`
`
` ,-
`
`
`
` +
`9
`
`ºtvw{vx»¼zw½¾
`
`~)
`* ( )?
`" (}
`+
`$
`
`0005
`
`
`
`Gqp &
` $
`
`
`¶mØkk
`ÙimÚkk
`hØØmj¸nkk
`¹j
`
`¦PUXKRNOLcXOLL
`\VXSNQdLZPONRNPQOLL
`NQLNQQPUXRNUVL
`ZcXKMXTVJRNTX\OgL
`dVQVKNTOLXQSLVYVL
`TXKVLWNRcLRcVL
`NQQPUXRNPQLZPWVKL
`XQSLd\PaX\LOTX\VL
`QVTVOOXKYLRPL
`TPMZVRVLVbbVTRNUV\YL
`NQLXLTcXQdNQdLL
`WPK\S
`
`ºtÇv˼ºxyv»vÛ
`
`k k
`
`¦PUXKRNOLMXSVLORKPQdLZKPdKVOOLNQL¢£¤¥^L_VLTPMZ\VRVSLXLMXÔPKLZPKRbP\NPLRKXQO`
`bPKMXRNPQgLKVNQbPKTVSLPJKL\VXSLNQLNQQPUXRNPQgLXQSLSV\NUVKVSLOP\NSLfQXQTNX\LZVKLbPK`
`MXQTV^L¡]MLTPQUNQTVSLWVLcXUVLXLORKPQdLbPJQSXRNPQLbPKLdKPWRcLNQLXLWPK\SLWcVKVL
`RcVLZPZJ\XRNPQLNOLXdNQdLXQSLcVX\RcTXKVLOYORVMOLQVVSLRPLSV\NUVKLÕJX\NRYLTXKVLMPKVL
`TPOR`VbbVTRNUV\Y^LLLL
`
` $,
` À + $ +
`
` + $Á++Â 7 } Ö- 8
`+ ,
` $-
`
`~
`
` , + * ) +)+"$+
` + *$
` $ ÀÁ++Â 7 }-×8 %
`
` -
`+
`*
`, *
` &"-
`+ , $Á++Â
-ÖÀ-$ $
`"
` &
`
`89$
` ,
`(
`* +
`)
`* + + $ " " !} & $ $ ) +))" ´$
`
`" $ ,
`(
`* +
` + } & $ -
`
` $ (
`,
` )
` "+ $
` $À " ++ "(
` À ( $ $ "
`$+
` ,
`
`
`+ "$++$$
` ,
`
` "+
` ( " ´$ , ) * + ( %
`
`
` $- *
`, ,*
`' $$ $,
` )$ " À
`"
` &
`
`89$
` ,
`(
`* +
`)
`* + + $ " " !} & $ $ ) +))" ´$
`
`" $ ,
`(
`* +
` + } & $ -
`
` $ (
`,
` )
` "+ $
` $À " ++ "(
` À ( $ $ "
`$+
` ,
`
`
`+ "$++$$
` ,
`
` "+
` ( " ´$ , ) * + ( %
`
`
` $- *
`, ,*
`' $$ $,
` )$ " À
$$ *+ * $+ "-
`
`? 8 & )$ " $ *
`
`9 "
`* ( +$" ) ,%
`*
`
`(
` )$*
`' $-
`
`¨µ !"
` (
` $(
`* ) ) $ *
` &"
`+ * & $ -p &
` $ $
`
` *
`( +$"+ * 9 ) " , $ $ & &)
`* + + $,
` +$
`
` "9+
`- $ + * 9 ) & ) &
` ", 8 $+ +$$
`9 + *%
`
` ´+ &9 +) , ,
`"-
`
`p &
` $?$ $$
`& +$Áp? Â
` +
` $$%" & $ $
`& +$
`, !
` *"
`
`
`
`? 8 & )$ " $ *
`
`9 "
`* ( +$" ) ,%
`*
`
`(
` )$*
`' $-
`
`¨µ !"
` (
` $(
`* ) ) $ *
` &"
`+ * & $ -p &
` $ $
`
` *
`( +$"+ * 9 ) " , $ $ & &)
`* + + $,
` +$
`
` "9+
`- $ + * 9 ) & ) &
` ", 8 $+ +$$
`9 + *%
`
` ´+ &9 +) , ,
`"-
`
`p &
` $?$ $$
`& +$Áp? Â
` +
` $$%" & $ $
`& +$
`, !
` *"
`
`
" 9" +
` +
` " (9 , "" $9
`, $ +
` $$
`8$ $$$
`
` )
`9 " , *
`
` "+ & 9, $-A)$, $
` "+" &
` $ & ,$ (
`
`7 }-
` +
` " (9 , "" $9
`, $ +
` $$
`8$ $$$
`
` )
`9 " , *
`
` "+ & 9, $-A)$, $
` "+" &
` $ & ,$ (
`
`7 }-
8 $ 9
` ) )8 ,,$ $ & ,$ (7 }-8 + * ,(
` *
` +
`%
`
`* ´
` $-
`
`p? ) $ 8 Ö * 9$
`" " )µ&, 8 $
`& ++
`$$+ ,-
`
`+ p? + "
` & ,
` "+ & 9, $ "+ $ $ & ,$ +
` $$p &
` $-
`
`0006
`
`
` ) )8 ,,$ $ & ,$ (7 }-8 + * ,(
` *
` +
`%
`
`* ´
` $-
`
`p? ) $ 8 Ö * 9$
`" " )µ&, 8 $
`& ++
`$$+ ,-
`
`+ p? + "
` & ,
` "+ & 9, $ "+ $ $ & ,$ +
` $$p &
` $-
`
`0006
`
`
`
`5=6 55E/
`
`p &
` $
`
q;
`
`njoĶomoÄkhijk¹·kmokmoohÚ·mho
`
`tuzw¾xǼzÇzÍt»{¼vwx¾z{vzÇ
`
`FvzÍÇtǾwv»{¾¼v»v½tÆwËxËvÍx»vÒ
`
`5x»zÍÍÊÒÉvzËËtx»¾v½zÈzËzÑÍv»vÉ
`
`zÍvz½vwx»x»»tuz¾xt»z»½Év
`
`Ívuvwz{x»{tÆwǾwt»{ËtÇx¾xt»x»
`
`Ívz½vwÏtwtÆwwvÇvzwȼtw{z»xÛz¾xt»
`
`Ǿwv»{¾¼v»v½tÆwËtÇx¾xt»x»@C3;Î
`
`Èz»ÈvwÑÊz½½x»{½v˾¼x»xyyÆ»tÐ
`
`¾tÇÆÈÈvv½ zwë5xǼyz»ÒɼtxÇ
`
`t»ÈtÍt{Êz»½ÑttǾx»{t˾xt»ÇÏtw
`
`wv¾xwx»{z»½É¼tÇvÍvz½vwǼxËz»½
`
` Æw½vuvÍtËyv»¾¾vzyǽvÍxuvwv½»vÉ
`
`ÈtyÑx»z¾xt»¾¼vwzËxvÇλ½Évzwv
`
`ÇÈxv»¾xÜÈËwtÉvÇÇÉxÍÍÑvyxÇÇv½ÎxÇ
`
`yv½xÈx»vÇÉx¾¼Çx{»xÜÈz»¾Ët¾v»¾xzÍ
`
`vÌËÍtwx»{»vɾvȼ»tÍt{xvǾ¼z¾ÉxÍÍ
`
`ÇÆÈÈvÇÇtwÒºzÊwz½»vwÒxÇz˼ÊÇxÈxz»
`
`¼vz;¼Ñv»vܾÇÏtwyxÍÍxt»ÇtÏËz¾xv»¾ÇÒ
`
`v»zÑÍvÆǾtz½½wvÇÇÆ»yv¾yv½xÈzÍ
`
`z»½zÇÈxv»¾xǾÉx¾¼Ç¾wt»{ÑÆÇx»vÇÇ
`
`x»ÈÍƽx»{ÝÞßàáâßãÏtw¼vzw¾ÏzxÍÆwvä
`
`»vv½Ñvx»{½wxuv»Ñʽwzyz¾xÈ
`
`zÈÆyv»z»½zËzÇÇxt»Ïtwz½uz»Èx»{
`
`åãâáÞßæçÏtwËÇtwxzÇxÇz»½t¾¼vw
`
`½vyt{wz˼xÈǼxϾÇÒÇÆȼzǽxÇvzÇvÇ
`
`wvÇvzwȼ¾¼wtÆ{¼ÈtÍÍzÑtwz¾xt»Î
`
`xÍÍ»vÇÇvÇäz»½èéàçêãÒ¾¼vÜwǾÑxtÇxyxÍzw
`
`zÇÇtÈxz¾v½Éx¾¼z{x»{Òz½½wvÇÇv½
`
`zËËwtuv½Æ»½vw»vÉwÆÍvÇx»¾¼v=/Î
`
`¾¼wtÆ{¼wv{v»vwz¾xuvyv½xÈx»vÎ
`
`5twytwv½v¾zxÍt»x»»tuz¾xt»Ò
`
`¼vÇvËwt½ÆȾǼvÍËÆ»½vwËx»tÆwÏƾÆwvÎ
`
`ÇvvËz{vGGÎ
`
`À $ $ $
`
`
`Á++Â
`
`¨* "(
` )
`$
` "$
` $ ) )
` (
`+ )
`$ )
`+$ *
`$ "
`
`$ + 9 + $- ) ,) ' )
` $*
`
`' " + " * '+
`
`
` ,
`$$ B 9 )Ö×À (Ö
`
`njoĶomoÄkhijk¹·kmokmoohÚ·mho
`
`tuzw¾xǼzÇzÍt»{¼vwx¾z{vzÇ
`
`FvzÍÇtǾwv»{¾¼v»v½tÆwËxËvÍx»vÒ
`
`5x»zÍÍÊÒÉvzËËtx»¾v½zÈzËzÑÍv»vÉ
`
`zÍvz½vwx»x»»tuz¾xt»z»½Év
`
`Ívuvwz{x»{tÆwǾwt»{ËtÇx¾xt»x»
`
`Ívz½vwÏtwtÆwwvÇvzwȼtw{z»xÛz¾xt»
`
`Ǿwv»{¾¼v»v½tÆwËtÇx¾xt»x»@C3;Î
`
`Èz»ÈvwÑÊz½½x»{½v˾¼x»xyyÆ»tÐ
`
`¾tÇÆÈÈvv½ zwë5xǼyz»ÒɼtxÇ
`
`t»ÈtÍt{Êz»½ÑttǾx»{t˾xt»ÇÏtw
`
`wv¾xwx»{z»½É¼tÇvÍvz½vwǼxËz»½
`
` Æw½vuvÍtËyv»¾¾vzyǽvÍxuvwv½»vÉ
`
`ÈtyÑx»z¾xt»¾¼vwzËxvÇλ½Évzwv
`
`ÇÈxv»¾xÜÈËwtÉvÇÇÉxÍÍÑvyxÇÇv½ÎxÇ
`
`yv½xÈx»vÇÉx¾¼Çx{»xÜÈz»¾Ët¾v»¾xzÍ
`
`vÌËÍtwx»{»vɾvȼ»tÍt{xvǾ¼z¾ÉxÍÍ
`
`ÇÆÈÈvÇÇtwÒºzÊwz½»vwÒxÇz˼ÊÇxÈxz»
`
`¼vz;¼Ñv»vܾÇÏtwyxÍÍxt»ÇtÏËz¾xv»¾ÇÒ
`
`v»zÑÍvÆǾtz½½wvÇÇÆ»yv¾yv½xÈzÍ
`
`z»½zÇÈxv»¾xǾÉx¾¼Ç¾wt»{ÑÆÇx»vÇÇ
`
`x»ÈÍƽx»{ÝÞßàáâßãÏtw¼vzw¾ÏzxÍÆwvä
`
`»vv½Ñvx»{½wxuv»Ñʽwzyz¾xÈ
`
`zÈÆyv»z»½zËzÇÇxt»Ïtwz½uz»Èx»{
`
`åãâáÞßæçÏtwËÇtwxzÇxÇz»½t¾¼vw
`
`½vyt{wz˼xÈǼxϾÇÒÇÆȼzǽxÇvzÇvÇ
`
`wvÇvzwȼ¾¼wtÆ{¼ÈtÍÍzÑtwz¾xt»Î
`
`xÍÍ»vÇÇvÇäz»½èéàçêãÒ¾¼vÜwǾÑxtÇxyxÍzw
`
`zÇÇtÈxz¾v½Éx¾¼z{x»{Òz½½wvÇÇv½
`
`zËËwtuv½Æ»½vw»vÉwÆÍvÇx»¾¼v=/Î
`
`¾¼wtÆ{¼wv{v»vwz¾xuvyv½xÈx»vÎ
`
`5twytwv½v¾zxÍt»x»»tuz¾xt»Ò
`
`¼vÇvËwt½ÆȾǼvÍËÆ»½vwËx»tÆwÏƾÆwvÎ
`
`ÇvvËz{vGGÎ
`
`À $ $ $
`
`
`Á++Â
`
`¨* "(
` )
`$
` "$
` $ ) )
` (
`+ )
`$ )
`+$ *
`$ "
`
`$ + 9 + $- ) ,) ' )
` $*
`
`' " + " * '+
`
`
` ,
`$$ B 9 )Ö×À (Ö
`,
`9 $+ $
`" "
9 " ,, "
`
`
`
`
` ++ 8µ " ,$-¨
` ' ,$ $
` (
`+
`+
` ( ,
` 989(
` $ +
`
`* " (9 , + &$(
`$ $(
`+$ "+) , ,$ *
` *
` + +$-
`
` À +
` $ +
`
`
`
`
` , + *
`Á++Â
`
` $ ( +$ *
` & ,) ) + *$(
` $89&
` , ,*" + $+ +
`
`
` $ "& + , )+
` &$ ( " , +) ,9 "" 9$ $ )) )+
`
`
`$9$ *$" &
`
` %
`" + *$ )
` )
` $-A) $ 8$ *
` &&
`
` "
`"+ $ )$9$ *- ) $ * ( +
` $"$+
` 9 "
`,
` +$ "
`%
`
`$ " ) $ ") )+
`$9$ *$ " , , "& (
` ) )9$ "
`
`
` * $-
`
`
`
`
`
`
` ++ 8µ " ,$-¨
` ' ,$ $
` (
`+
`+
` ( ,
` 989(
` $ +
`
`* " (9 , + &$(
`$ $(
`+$ "+) , ,$ *
` *
` + +$-
`
` À +
` $ +
`
`
`
`
` , + *
`Á++Â
`
` $ ( +$ *
` & ,) ) + *$(
` $89&
` , ,*" + $+ +
`
`
` $ "& + , )+
` &$ ( " , +) ,9 "" 9$ $ )) )+
`
`
`$9$ *$" &
`
` %
`" + *$ )
` )
` $-A) $ 8$ *
` &&
`
` "
`"+ $ )$9$ *- ) $ * ( +
` $"$+
` 9 "
`,
` +$ "
`%
`
`$ " ) $ ") )+
`$9$ *$ " , , "& (
` ) )9$ "
`
`
` * $-
`
`
`
` & $
`
` '9*
`' $
`
`
`
` & $
`
` '9*
`' $
`
`
'(
` )
`$ $ *
` &
`´+ & $$ "+ +9 $
`, %
`
`! $
` ,(
`,
` ) " & -¨) & $ "
`
` + ,
` )
`
`89( +$ , )8$ $$$
` , ) , $( " " &$ ,(
`,
` )- )
`
`
`& +
` !
`* ( +
` , +
` $$" & $ $ "+
` *
`$)
`"$
`& +$
`
`
`
`
`
`+ $ 8 $- "
` ,
` ,$ * (
`"
`,"& * ( + $
`
` ) + & & (
` )
` ) +
` $ ,+ +9-
`
`#" ' ) 'p &
` $ $$ + $(
`+ , " &
`$
` ,
`$ $"
` ,
` " (
`
`$ , µ+ +) ,$
`+ * 9- $ " ) '$
`$)
`) "
`$(
` )
`+ "
`
`$
` -
`
`
`
` +
`9
`
`ºtÇv˼ºxyv»vÛ
`
`~) (+ &+
`
`
`
`~ ,
` $
`
`0007
`
`
` )
`$ $ *
` &
`´+ & $$ "+ +9 $
`, %
`
`! $
` ,(
`,
` ) " & -¨) & $ "
`
` + ,
` )
`
`89( +$ , )8$ $$$
` , ) , $( " " &$ ,(
`,
` )- )
`
`
`& +
` !
`* ( +
` , +
` $$" & $ $ "+
` *
`$)
`"$
`& +$
`
`
`
`
`
`+ $ 8 $- "
` ,
` ,$ * (
`"
`,"& * ( + $
`
` ) + & & (
` )
` ) +
` $ ,+ +9-
`
`#" ' ) 'p &
` $ $$ + $(
`+ , " &
`$
` ,
`$ $"
` ,
` " (
`
`$ , µ+ +) ,$
`+ * 9- $ " ) '$
`$)
`) "
`$(
` )
`+ "
`
`$
` -
`
`
`
` +
`9
`
`ºtÇv˼ºxyv»vÛ
`
`~) (+ &+
`
`
`
`~ ,
` $
`
`0007
`
`
`
`6 | Novartis Annual Report 2015
`sqp &
` $
`
`
`KEY PERFORMANCE INDICATORS
`ìíkÅjØhjl·okmom·hjnkk
`CONSOLIDATED HIGHLIGHTS
`honh¹m·k¶mĶ¹mĶn
`
` 2015 2014 USD currencies
`
`
`
`
`
`Financial
`Øïððñï
`KEY FIGURES1
`3
`% Change
`(in USD millions, unless indicated otherwise)
`<05=/
`Constant
`
`
`
`À~) ,
`Á 7 }* $ $$ " + " )
` $Â
`
`
`
`
`
`
`
`
`
`
`
`~ $
`
`
`
`
`
`
`
`
`
`
`7 }
`+
`
` + $
`— 5
`52 180
`49 414
`Net sales to third parties from continuing operations
`5
`
`
`
`ò
`
`
×
`
` Ö
`
`p $ $ )
`"
` $(
` *+ ,
` $
`— 19
`11 089
`8 977
`Operating income from continuing operations
`—2
`
`
`
`
`òÖ
`
` ×Ö
`
`×Ö
`
`
` , + *(
` *+ ,
` $
`ò
`
` Ö
`
`p $ $ )
`"
` $(
` *+ ,
` $
`— 19
`11 089
`8 977
`Operating income from continuing operations
`—2
`
`
`
`
`òÖ
`
` ×Ö
`
`×Ö
`
`
` , + *(
` *+ ,
` $
`ò
`21.3
`18.2
`Return on net sales (%)
`
`
`
`
`
`
-
`
`×-
`
`×-
`
`óóó
` $ $ÁÀÂ
`—34
`10 727
`7 028
`Net income from continuing operations
`
`
`
`ò
`
`
`
`
`
`
×
`
`p + *(
` *+ ,
` $
`—447
`10 766
`Net income/loss from discontinued operations2
`
`
`
`
`
`p + *(
` *+ ,
` $
`—447
`10 766
`Net income/loss from discontinued operations2
`
`
`
`
`10280
`17 794
`Net income2
`73
`
`ò
`
`
`
`
`p + *ô $$(
` *" $+ "
` $
`
`
`
`
`
`
`
×
`
`Ö
`
`p + *
`
`—33
`4.39
`2.92
`Basic earnings per share3 (USD) from continuing operations
`
`
`
`
`ò
`
`
` -Ö
`
`
`
`
`Ö
`
`p + *
`
`—33
`4.39
`2.92
`Basic earnings per share3 (USD) from continuing operations
`
`
`
`
`ò
`
`
` -Ö
`
`
`
-Ö
`
`
`? $ +
` ,$
`$)
`Á7 }Â(
` *+ ,
` $
`—O.18
`4.48
`Basic earnings per sharezva (USD) from discontinued operations
`
`
`
`
`
`
`ò -×
`
` - ×
`
`? $ +
` ,$
`$)
`
`Á7 }Â(
` *" $+ "
` $
`76
`4.21
`7.40
`Total basic earnings per share2-3 (USD)
`
`
`
`
`
`
`ò -×
`
` - ×
`
`? $ +
` ,$
`$)
`
`Á7 }Â(
` *" $+ "
` $
`76
`4.21
`7.40
`Total basic earnings per share2-3 (USD)
`
`
`
`
`
`
`
` -
`
`
` -
`
`-
`
`A 8 $ +
` ,$
`$)
`
`Á7 }Â
`— 5
`14 473
`13 790
`Core operating income from continuing operations
`
`
`
`ò
`
`
`
`Ö
`
`~
`
` , + *(
` *+ ,
` $
`27.7
`27.9
`Core return on net sales (%)
`
`
`
`
`
-
`
`
`
`
-Ö
`
`óóó~
`
`
` $ $ÁÀÂ
`9
`— 5
`12 653
`12 041
`Core net income from continuing operations
`
`
`
`ò
`
`
`
`óóó~
`
`
` $ $ÁÀÂ
`9
`— 5
`12 653
`12 041
`Core net income from continuing operations
`
`
`
`ò
`
`
`
`
`
`
`
`~
` + *(
` *+ ,
` $
`10
`—3
`5.19
`5.01
`Core earnings per share3 (USD) from continuing operations
`
`
`
`
`
`
`ò
`-Ö
`-
`
`~
`
` ,$
`$)
`Á7 }Â(
` *+ ,
` $
`
`
`
`— 15
`10 934
`9 259
`Free cash flow from continuing operations
`Free cash flow — 16 9 029 10 762
`
`
`
`
`
`
`
`
`+ $)î (
` *+ ,
` $
`Ö
Ö
`
` Ö
`
`ò
`
`
`
`
`Ö
`
` Ö
`
`ò
`
`
`
`
`Ö
Ö
`
`
`
`
`
`ò
`
`
`+ $)î
`SHARE INFORMATION
`
`2015
`2014
`% Change
`/5
`
`
`
`
`
`
`
`
`
`À~) ,
`92.35
`86.80
`Share price at year-end (CH F)
`— 6
`
`
`
`Ö
-
`
`×-×
`
` )
`
` + 9
`% "Á~Â
`ò
`
`92.66
`86.04
`ADR price at year-end (USD)
`— 7
`
`
`
`Ö
`
`×-×
`
` )
`
` + 9
`% "Á~Â
`ò
`
`92.66
`86.04
`ADR price at year-end (USD)
`— 7
`
`
`
`Ö
-
`
`×-
`
` }
` + 9
`% "Á7 }Â
`ò
`
`2.60
`2.70
`Dividend“ (CH F)
`4
`
`
`
`
`
`
`
`} & " "Á~Â
`
`
`×-
`
` }
` + 9
`% "Á7 }Â
`ò
`
`2.60
`2.70
`Dividend“ (CH F)
`4
`
`
`
`
`
`
`
`} & " "Á~Â
`
-
`
`
`
`
-
`
`62
`93
`Payout ratio5 based on continuing operations (%)
`
`
`
`
`
`
` 9
` 8 $" + ,
` $ÁÀÂ
`Ö
`
`
`
`62
`93
`Payout ratio5 based on continuing operations (%)
`
`
`
`
`
`
` 9
` 8 $" + ,
` $ÁÀÂ
`Ö
`
`
`
`
`Payout ratio5 (%)
`37
`65
`
`
`
`
` 9
` ÁÀÂ
`
`
`
`
`
`
`
`— 18
`
`ò×
`
`91
`
`Ö
`— 17
`
`ò
`
`
`94
`
`Ö
`10
`
`
`
`
`Ö
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`FURTHER DETAIL
`5=>
`On our performance,
` »tÆwËvwÏtwyz»ÈvÒ
`see page 24
`ÇvvËz{v@G
`On our financial report,
` »tÆwÜ»z»ÈxzÍwvËtw¾Ò
`see page 138
`ÇvvËz{v34
`
`1 This Annual Report includes non-IFRS financial measures such as core results,
`constant currencies and free cash flow. Novartis believes that investor understanding
`
`A) $
` +"$ % µ + * $
`$$+) $+
`
`$ $
`of the Group's performance is enhanced by disclosing these non-IFRS measures.
`+ $ +
`
` + $ "(
`+ $)î -p &
` $8 &$ ) &$
` "
`$ " ,
`Core measures exclude items that can vary significantly from year to year, such as the
`
` ( )
` #$
`(
`* + $ ) +"89" $+ $ , )$ % * $
`$-
`impact of certain significant exceptional and other items related to disposals and
`~
`* $
`$+" *$ ) + &
`9$ , µ+ 9(
` *9
` 9
`$+) $ )
`acquisitions, as well as other exceptional items over a USD 25 million threshold.
` * + (+
` $ , µ+ + " )
` *$
` " " $ $ $ "
`Constant currency calculations have the goal of eliminating exchange rate effects so
` +B $ $ $ $ )
`+ *$ &
` 7 }
* )
`$) "-
`that an estimate can be made of underlying changes in the consolidated income
`~ $ +
`
` +9+ + $) & ), ( * ,+) ,
` ´+ $$
`statement excluding the impact of fluctuations in exchange rates. Free cash flow is an
` ) $ * + 8* " ( "
`9 ,+) ,$ )+ $ " " + *
`indicator of the Group's ability to operate without additional borrowing or the use of
`$ * +" , ) * + (î+ $ +) ,
` $-
`+ $)î $
`existing cash. Further details of non-IFRS measures, including reconciliation tables,
` " +
` ( )
` #$ 8 9
` ) "" 8
`
` ,
` )$ (
`can be found starting on page 165.
` $ ,+ $)-
` )
`" $ ( % * $
`$ +" ,
`+ + 8$
`+ 8( "$
` , ,-
`
`2 Net income from discontinued operations and net income of the Group include
`exceptional divestment gains. Continuing and discontinued operations are defined
`
`$) "-
`that an estimate can be made of underlying changes in the consolidated income
`~ $ +
`
` +9+ + $) & ), ( * ,+) ,
` ´+ $$
`statement excluding the impact of fluctuations in exchange rates. Free cash flow is an
` ) $ * + 8* " ( "
`9 ,+) ,$ )+ $ " " + *
`indicator of the Group's ability to operate without additional borrowing or the use of
`$ * +" , ) * + (î+ $ +) ,
` $-
`+ $)î $
`existing cash. Further details of non-IFRS measures, including reconciliation tables,
` " +
` ( )
` #$ 8 9
` ) "" 8
`
` ,
` )$ (
`can be found starting on page 165.
` $ ,+ $)-
` )
`" $ ( % * $
`$ +" ,
`+ + 8$
`+ 8( "$
` , ,-
`
`2 Net income from discontinued operations and net income of the Group include
`exceptional divestment gains. Continuing and discontinued operations are defined
`
`p + *(
` *" $+ "
` $ " + * ( )
` +"
`on page 147.
`+ " &$ * , $-~ , "" $+ "
` $
`"µ "
`2015 weighted average number of shares outstanding: 2 403 million (2014: 2 426
` , -
`million)
`
`
,) " &
` , *8
` ($)
`$ $ " ,Ã
` , *8
` ($)
`$ $ " ,Ã
* Á
Ã
`Dividend 2015: proposal to shareholders for approval at the Annual General
`* Â
`Meeting on February 23, 2016
`
`} & " "
`Dividend 2015: proposal to shareholders for approval at the Annual General
`* Â
`Meeting on February 23, 2016
`
`} & " "
Ã
` $ $)
`) "
`$(
`
` & )
`
`Payout ratio 2015 is calculated by converting into USD the proposed total gross
` , 8
`
`9
` $ $)
`) "
`$(
`
` & )
`
`Payout ratio 2015 is calculated by converting into USD the proposed total gross
` , 8
`
`9
`dividend amount in CHF at the CHF—USD exchange rate of December 31,2015
`
` 9
`
`dividend amount in CHF at the CHF—USD exchange rate of December 31,2015
`
` 9
`
$+ + "89+ &
` , 7 } )
` $" ,
` $$
`based on an estimated number of shares outstanding on dividend payment date
`" & " " * ~ )~%7 }+) ,
` (}+*8
`
` , 7 } )
` $" ,
` $$
`based on an estimated number of shares outstanding on dividend payment date
`" & " " * ~ )~%7 }+) ,
` (}+*8
`
`and dividing it by the USD consolidated net income from continuing operations and
`8 $" $ * " *8
` ($)
`$ $ " , " & " " 9* "
`net income attributable to shareholders of Novartis AG in the Group's 2015
` "" & " , 89 )7 }+ $ " " + *(
` *+ ,
` $ "
`consolidated financial statements.
` + *
` 8 8 $)
`) "
`$ (p &
` $ )
` #$
`+ $ " "µ + $ * $-
`
`0008
`
`0008
`
`
`
`KEY PERFORMANCE INDICATORS CONSOLIDATED HIGHLIGHTS
`
`<015 > / / >>/
`
`Novartis Annual Report 2015 | 7
`p &
` $
`
q:
`
`Innovation
`mððõöïð
`
`KEY FIGURES1
`2015
`2014
`3
`
`
`<05=/
`
`
`
`Innovation
`mððõöïð
`
`KEY FIGURES1
`2015
`2014
`3
`
`
`<05=/
`
`
`
`
`Projects entering portfolio 2'3
`25
`13
`
`
`
`
` + $
` ,
` (
`
`@;
`
`
`Ongoing Phase III programs"
`37
`37
`
`
`
`
` , ,) $
` ,
` *$
`4:
`
`
`US FDA breakthrough therapy designations5
`0
`2
`
`
`
`7 } 8
` ' )
` ,) )
` 9"$ , $
`15
`14
`Major submissions (US, EU, JP)6
`
`
`
`
`3G
`
`
`$8* $$ $Á7 7÷Â
`
`14
`20
`Major approvals (US, EU, JP)6v7
`
`
`
`
`
`
` & $Á7 7÷Â
`
`@C
`
`
`New molecular entity (NME) approvals8
`6
`4
`×
`
`óóóp * +
` 9ÁpÂ
` & $
`
`C
`
`s
`
`
`
`
`
`
`
` + $
` ,
` (
`
`@;
`
`
`Ongoing Phase III programs"
`37
`37
`
`
`
`
` , ,) $
` ,
` *$
`4:
`
`
`US FDA breakthrough therapy designations5
`0
`2
`
`
`
`7 } 8
` ' )
` ,) )
` 9"$ , $
`15
`14
`Major submissions (US, EU, JP)6
`
`
`
`
`3G
`
`
`$8* $$ $Á7 7÷Â
`
`14
`20
`Major approvals (US, EU, JP)6v7
`
`
`
`
`
`
` & $Á7 7÷Â
`
`@C
`
`
`New molecular entity (NME) approvals8
`6
`4
`×
`
`óóóp * +
` 9ÁpÂ
` & $
`
`C
`
`s
`
`
`
`
`
`
`
`8
`
`ù
`
`
`
`
`
`
`1 547 / 1 131
`1 299 / 755
`
`
`3@DDû:;;
` ô
`98.4
`97.9
`
`
`DÎG
`
`Ö-Ö
`
`
`
`-
`Soc1al
`nñï
`
`ACCESS
`2015
`2014
`
`
`//
`
`
`
`
`939
`972
`Total patients reached (millions)
`
`
`ÖÖ
`D:@
`
`A $
` +)"Á* $Â
`72
`66
`Patients reached through access programs (millions)
`
`
`
`ss
`
`óóó $
` +)" )
` ,) ++$$
` ,
` *$Á* $Â
`10
`12
`People reached through training, health education and service delivery (millions)
`
`
`
`3@
`
`
` +)" )
` ,)
` ,) )"+ "$
`& +" &
`9Á* $Â
`100%
`100%
`Top 20 global burden of disease conditions addressed by products and pipeline9
`
`
`Ö
` À
`3CCú
`A
, 8 8
`" (" $ $+ " $ ""
`$$"89
` "+ $ "
`
`
`
`PEOPLE
`
`1 1
`
`
`118 700 / 122 966 117 809 / 122 113
`Full-time equivalent positions / headcount10
`
`
`
`33:CCû3@@Dss
`× Öô
`" (" $ $+ " $ ""
`$$"89
` "+ $ "
`
`
`
`PEOPLE
`
`1 1
`
`
`118 700 / 122 966 117 809 / 122 113
`Full-time equivalent positions / headcount10
`
`
`
`33:CCû3@@Dss
`× Öô
`% *B & $ $ô) "+
`
`7.3 / 13.5
`7.0 / 13.0
`Turnover: % voluntary / % overall
`
`
`:Î4û34Î;
`
`- ô-
`A
` &
`ÃÀ&
`9ôÀ &
`
`41 / 27
`40 / 18
`Women in management: % of management11 / % of Board of Directors
`
`
`
`G3û@:
`
`
` ô×
`¨ * * ,* ÃÀ (* ,*
`ôÀ (?
`" (}
`+
`$
`144 / 109
`147 / 109
`Associate nationalities / associate nationalities in management11
`
`
`
`3GGû3CD
`
` ô Ö
` $$ + $ô $$ + $ * ,*
`
`0.11
`0.12
`Lost-time injury and illness rate (per 200 000 hours worked)12
`
`
`
`% *B & $ $ô) "+
`
`7.3 / 13.5
`7.0 / 13.0
`Turnover: % voluntary / % overall
`
`
`:Î4û34Î;
`
`- ô-
`A
` &
`ÃÀ&
`9ôÀ &
`
`41 / 27
`40 / 18
`Women in management: % of management11 / % of Board of Directors
`
`
`
`G3û@:
`
`
` ô×
`¨ * * ,* ÃÀ (* ,*
`ôÀ (?
`" (}
`+
`$
`144 / 109
`147 / 109
`Associate nationalities / associate nationalities in management11
`
`
`
`3GGû3CD
`
` ô Ö
` $$ + $ô $$ + $ * ,*
`
`0.11
`0.12
`Lost-time injury and illness rate (per 200 000 hours worked)12
`
`
`
`CÎ33
` $ % *
`9 " $$
` Á
`
)
`$
`'"Â
`
`
`
` -
`$
`'"Â
`
`
`
` -
`
`ETHICS
`/
`
`Misconduct cases reported / allegations substantiated 13
`
` $+ "+ + $$
`
` "ô , $$8$ "
`
`Regulatory inspections without major findings (%)
`,
`9 $+ $ ) *
`µ " ,$ÁÀÂ
`ENVIRONMENTAL SUSTAINABILITY
`
`6 /=/0
`
`Greenhouse gas emissions, total Scope 1 and Scope 2 (1 000 t) 1“
`
`
` ) $, $* $$ $ + " +
Á
Â
`
`Water discharge (million m3)
`
`¨
`" $+)
`,Á* *
`Â
`
`
`
`
`
`
`1 350.7
`
`34;CÎ:
`
`16.6
`
`3sÎs
`
`
`
`
`1 361.9
`
`-Ö
`17.0
`
`-
`
`
`
`
`
`FURTHER DETAIL
`5=>
`0n innovation,
` »x»»tuz¾xt»Ò
`see page 44
`ÇvvËz{vGG
`
`FURTHER DETAIL
`5=>
`0n social,
` »ÇtÈxzÍÒ
`see page 62
`ÇvvËz{vs@
`
`1
`
`Includes Pharmaceuticals, Sandoz biosimilars and Alcon ophthalmic
`pharmaceuticals only
`
` +"$)
`* + + $ " !8 $ *
`$ " + ) ) * +
`2 Includes clinical Phase II programs only, post proof of concept. First patient, first
`)
`* + + $ 9
`visit (FPFV) has occurred. Also include small molecules, biologics; new fixed-dose
`
`
`Water discharge (million m3)
`
`¨
`" $+)
`,Á* *
`Â
`
`
`
`
`
`
`1 350.7
`
`34;CÎ:
`
`16.6
`
`3sÎs
`
`
`
`
`1 361.9
`
`-Ö
`17.0
`
`-
`
`
`
`
`
`FURTHER DETAIL
`5=>
`0n innovation,
` »x»»tuz¾xt»Ò
`see page 44
`ÇvvËz{vGG
`
`FURTHER DETAIL
`5=>
`0n social,
` »ÇtÈxzÍÒ
`see page 62
`ÇvvËz{vs@
`
`1
`
`Includes Pharmaceuticals, Sandoz biosimilars and Alcon ophthalmic
`pharmaceuticals only
`
` +"$)
`* + + $ " !8 $ *
`$ " + ) ) * +
`2 Includes clinical Phase II programs only, post proof of concept. First patient, first
`)
`* + + $ 9
`visit (FPFV) has occurred. Also include small molecules, biologics; new fixed-dose
`
` +"$+ + ) $
` ,
` *$ 9 $
` ( (+ + -
`$ µ
`$
`combinations of existing active pharmaceutical ingredients (APIs); and new target
`& $ ÁHÂ) $ ++
`
`"- $ +"$* * +$8 , +$ø µ"%" $
`indications, defined as new disease or new line of treatment (e.g., first— vs.
`+ *8 $ ( $ , + &)
`* + + ,
`" $Á $Âø "
`,
`second-line). Counted by indication and not compound
` " + $"µ " $ " $ $
` (
` * Á-,-µ
`$ %&$-
`3 This number has been adjusted due to an internal reporting errror. In 2014, we
`$+ "% Â-~ "89 " + " + * "
`reported it as 30.
`
`A) $ *8
`) $8 "$ ""
`
`
` ,
`
`
`
`-
`‘ Includes projects with FPFV in a Phase III study but not yet filed in US, EU orJapan
`
`
` " $ -
`5 Therapies under development by Novartis designated as breakthrough therapies by
`
` +"$
` + $ )H ) $$ "98 9 µ" 7 7
`÷
`the US Food and Drug Administration
`
`A)
` $ "
`"& * 89p &
` $"$ , " $8
` ' )
` ,) )
` $89
`5 Includes small molecules, biologics; new fixed-dose combinations of existing APIs;
` )7 " "}
`, "* $
`
`and new target indications, defined as new disease or new line of treatment
`
` +"$$* * +$8 , +$ø µ"%" $+ *8 $ ( $ , $ø
`(e.g., first— vs. second-line)
` "
`, " + $"µ " $ " $ $
` (
` *
`7 This number has been adjusted due to an internal reporting errror. In 2014, we
`Á-,-µ
`$ %&$-$+ "% Â
`reported it as 13.
`
`A) $ *8
`) $8 "$ ""
`
`
` ,
`
`
`
`-
`‘ Includes projects with FPFV in a Phase III study but not yet filed in US, EU orJapan
`
`
` " $ -
`5 Therapies under development by Novartis designated as breakthrough therapies by
`
` +"$
` + $ )H ) $$ "98 9 µ" 7 7
`÷
`the US Food and Drug Administration
`
`A)
` $ "
`"& * 89p &
` $"$ , " $8
` ' )
` ,) )
` $89
`5 Includes small molecules, biologics; new fixed-dose combinations of existing APIs;
` )7 " "}
`, "* $
`
`and new target indications, defined as new disease or new line of treatment
`
` +"$$* * +$8 , +$ø µ"%" $+ *8 $ ( $ , $ø
`(e.g., first— vs. second-line)
` "
`, " + $"µ " $ " $ $
` (
` *
`7 This number has been adjusted due to an internal reporting errror. In 2014, we
`Á-,-µ
`$ %&$-$+ "% Â
`reported it as 13.
`
`A) $ *8
`) $8 "$ ""
`
`
` ,
`
`
`
`-
`
`
` " $-
`
`3 Continuing operations
`9 As defined by the US-based Institute for Health Metrics and Evaluation, excluding
`×
`~ ,
` $
`injuries
`Ö
` $"µ "89 )7 %8 $" $ (
` )
` +$ "& +" ,
`1° Headcount reflects the total number of associates in our payroll systems. Full-time
`
` $
`equivalent adjusts headcount for associates working less than 100%. All data as of
`
` "+
`î+ $ ) *8
` ( $$ + $
` 9
` $9$ *$-% *
`December 31
`B & "$ $) "+ (
` $$ + $
`' ,$$ ) À- " $ (
`11 Management defined locally
`}+*8
`
`12 Data include Novartis associates and third-party personnel managed by Novartis
`
` ,* "µ " + 9
`associates
`
`
`
` " $-
`
`3 Continuing operations
`9 As defined by the US-based Institute for Health Metrics and Evaluation, excluding
`×
`~ ,
` $
`injuries
`Ö
` $"µ "89 )7 %8 $" $ (
` )
` +$ "& +" ,
`1° Headcount reflects the total number of associates in our payroll systems. Full-time
`
` $
`equivalent adjusts headcount for associates working less than 100%. All data as of
`
` "+
`î+ $ ) *8
` ( $$ + $
` 9
` $9$ *$-% *
`December 31
`B & "$ $) "+ (
` $$ + $
`' ,$$ ) À- " $ (
`11 Management defined locally
`}+*8
`
`12 Data include Novartis associates and third-party personnel managed by Novartis
`
` ,* "µ " + 9
`associates
`
`} +"p &
` $ $$ + $ " )
`"%
` 9
`$ * ,"89p &
` $
`13 Reporting has changed from assessing cases to assessing allegations. Because one
` $$ + $
`case can have more than one allegation, the assessment per allegation is higher
`
`
` ,) $+) ,"(
` * $$$$ ,+ $$ $$$$ , , $-?+ $
`than the previously reported assessment per case. Furthermore, numbers are
`+ $+ ) &*
` ) , ) $$$$*
` , $) ,)
`
`based on the date a misconduct case is reported, whereas previously they were
` ) )
`& $9
`
` " $$$$*
`+ $-
` )
`*
` *8
`$
`
`based on the date a misconduct case was assigned for investigation. 2014 data
`8 $" )" * $+ "+ + $ $
`
` " )
` $
`& $9 )9
`
`have been restated following the new methodology.
`8 $" )" * $+ "+ + $ $ $$ , "(
` &$ , -
"
`1‘ Scope 1: combustion and process, and vehicles; Scope 2: purchased energy
`) &8
`$ "( , ) * ) " ,9-
`
` + Ã+ *8$ "
` +$$ "&) +$ø +
`1‘ Scope 1: combustion and process, and vehicles; Scope 2: purchased energy
`) &8
`$ "( , ) * ) " ,9-
`
` + Ã+ *8$ "
` +$$ "&) +$ø +
Ã
`+) $"
`,9
`
`0009
`
`0009
`
`
`+) $"
`,9
`
`0009
`
`0009
`
`
`
`8 | Novartis Annual Report 2015
`qp &
` $
`
`
`2015 AT A GLANCE
` k·k·kĹ·o
`
`Who we are
`ükýk
`Novartis is a global healthcare company based in Basel,
`p &
` $ $ , 8 ) )+
`+ * 98 $" ? $
`Switzerland, with roots dating back more than 150 years. We
` !
` " )
` $" ,8 +'*
` ) 9
`$-¨
`provide healthcare solutions that address the evolving needs
`
` & ") )+
`$ $ ) ""
`$$ )& & , "$
`of patients and societies worldwide. Novartis products are
`
` ( $ "$ + $
`" "-p &
` $
` "+ $
`
`available in more than 180 countries and they reached nearly
` & 8 *
` ) × ó+
` $ " )9
` +)"
`9
`1 billion people globally in 2015. About 123 000 people of
`144 nationalities work at Novartis around the world.
`ó8 , 8 9
- 8
(
` $
`' p &
` $
` " )
`"-
`
`
`USD 15 trillion. Governments and health insurers are increas-
`7 }
` - &
` * $ ") ) $
`
`$
` +
` $%
`ingly searching for ways to keep spending in check. They are
` ,9$
`+) ,(
` 9$ '$ " , +)+'-A)9
`
`focusing on the value they receive, based on tangible benefits
`( +$ , )& )9
`+ &8 $" , 88 µ $
`for patients and healthcare systems.
`(
` $ ") )+
`$9$ *$-
`These developments validate our focus on innovation and
`A)$"& * $& "
`( +$ & "
`global scale, and underscore the need for collaboration to rein-
`, 8 $+ " "
`$+
` ) "(
`+ 8
`
` %
`force our know-how in areas ofemergingscience and technology.
`(
`+
`' %)
` $ (*
`, ,$+ + " +) ,9-
`
`
`FURTHER DETAIL
`Visit www.novartis.com/about-us
`5=>
`6xÇx¾ÉÉÉλtuzw¾xÇÎÈtyûzÑtƾÐÆÇ
`
`FURTHER DETAIL
`5=>
`On our environment, see page 14
` »tÆwv»uxwt»yv»¾ÒÇvvËz{v3G
`
`Our environment
`hþkðõïð ðök
`The world's rapidly growing and aging population is driving
`A)
`"#$
` "9,
` , " , , $"
` & ,
`changes in healthcare, presenting both new opportunities and
`+) ,$ ) )+
`
`$ ,8 )
` $ "
`new challenges for Novartis. The global population will increase
` +) ,$(
`p &
` $-A), 8 +
` $
`by more than 1 billion people by 2030, projects the United
`89*
` ) 8 89
` $
`' p &
` $
` " )
`"-
`
`
`USD 15 trillion. Governments and health insurers are increas-
`7 }
` - &
` * $ ") ) $
`
`$
` +
` $%
`ingly searching for ways to keep spending in check. They are
` ,9$
`+) ,(
` 9$ '$ " , +)+'-A)9
`
`focusing on the value they receive, based on tangible benefits
`( +$ , )& )9
`+ &8 $" , 88 µ $
`for patients and healthcare systems.
`(
` $ ") )+
`$9$ *$-
`These developments validate our focus on innovation and
`A)$"& * $& "
`( +$ & "
`global scale, and underscore the need for collaboration to rein-
`, 8 $+ " "
`$+
` ) "(
`+ 8
`
` %
`force our know-how in areas ofemergingscience and technology.
`(
`+
`' %)
` $ (*
`, ,$+ + " +) ,9-
`
`
`FURTHER DETAIL
`Visit www.novartis.com/about-us
`5=>
`6xÇx¾ÉÉÉλtuzw¾xÇÎÈtyûzÑtƾÐÆÇ
`
`FURTHER DETAIL
`5=>
`On our environment, see page 14
` »tÆwv»uxwt»yv»¾ÒÇvvËz{v3G
`
`Our environment
`hþkðõïð ðök
`The world's rapidly growing and aging population is driving
`A)
`"#$
` "9,
` , " , , $"
` & ,
`changes in healthcare, presenting both new opportunities and
`+) ,$ ) )+
`
`$ ,8 )
` $ "
`new challenges for Novartis. The global population will increase
` +) ,$(
`p &
` $-A), 8 +
` $
`by more than 1 billion people by 2030, projects the United
`89*
` ) 8 89
` + $ )7 "
`Nations, with most of that growth occurringin developing coun-
`p $ )* $ ( ) ,
` ) ++
`
` , "& ,+ %
`tries. People over age 60 are the fastest-growing population
`
` $- &
` ,
` )( $ $ %,
` ,
`segment, expected to add 500 million people and reach 1.4 bil-
`$,* + " "" * "
` +)- 8 %
`lion by 2030.
` 89
` + $ )7 "
`Nations, with most of that growth occurringin developing coun-
`p $ )* $ ( ) ,
` ) ++
`
` , "& ,+ %
`tries. People over age 60 are the fastest-growing population
`
` $- &
` ,
` )( $ $ %,
` ,
`segment, expected to add 500 million people and reach 1.4 bil-
`$,* + " "" * "
` +)- 8 %
`lion by 2030.
` 89
-
`These factors are behind increasing demand for health-
`A)$( +
`$
`8) " +
` $ ,"* "(
`) )%
`care worldwide. |f current growth rates continue, healthcare
`+
`
`" "-(+
`
` ,
` )
` $+ ) )+
`
`spending will
`likely more than double by 2025, exceeding
`$ " , '9*
` ) " 889
`These factors are behind increasing demand for health-
`A)$( +
`$
`8) " +
` $ ,"* "(
`) )%
`care worldwide. |f current growth rates continue, healthcare
`+
`
`" "-(+
`
` ,
` )
` $+ ) )+
`
`spending will
`likely more than double by 2025, exceeding
`$ " , '9*
` ) " 889
+" ,
`
`Our strategy
`hþköö
`We believe Novartis is well prepared for a world with a growing,
`¨8 &p &
` $ $
`
`"(
`
`" ) ,
` ,
`aging population and evolving healthcare needs. Our mission,
` , , "& & ,) )+
` "$-
`* $$
`vision and strategy support the creation of long-term value for
`& $ "$
` ,9$
` )+
` ( ,%
`*& (
`
`our company, our shareholders and society.
`
`+ * 9
`$)
`) "
`$ "$ + 9-
`Our mission is to discover new ways to improve and extend
`
`* $$ $ " $+ &
` 9$ *
` & " "
`people's lives. Our vision is to be a trusted leader in changing
` #$ &$-
`& $ $ 8
`$ " "
` +) , ,
`the practice of medicine. Our strategy is to use science-based
` )
` + + (*" + -
`$
` ,9 $ $$+ +%8 $"
`innovation to deliver better outcomes for patients and to lead
` & " &
`8
`
`
`Our strategy
`hþköö
`We believe Novartis is well prepared for a world with a growing,
`¨8 &p &
` $ $
`
`"(
`
`" ) ,
` ,
`aging population and evolving healthcare needs. Our mission,
` , , "& & ,) )+
` "$-
`* $$
`vision and strategy support the creation of long-term value for
`& $ "$
` ,9$
` )+
` ( ,%
`*& (
`
`our company, our shareholders and society.
`
`+ * 9
`$)
`) "
`$ "$ + 9-
`Our mission is to discover new ways to improve and extend
`
`* $$ $ " $+ &
` 9$ *
` & " "
`people's lives. Our vision is to be a trusted leader in changing
` #$ &$-
`& $ $ 8
`$ " "
` +) , ,
`the practice of medicine. Our strategy is to use science-based
` )
` + + (*" + -
`$
` ,9 $ $$+ +%8 $"
`innovation to deliver better outcomes for patients and to lead
` & " &
`8
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
